FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 315:1115-1119 October 30, 1986 Number 18 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

The McCune-Albright syndrome is characterized by cafe au lait spots, fibrous dysplasia of bones, and sexual precocity. Girls with precocious puberty due to this syndrome have episodic increases in serum estrogen levels together with the formation of large ovarian cysts. The serum gonadotropin levels are typically suppressed, and the precocious puberty has not responded to treatment with long-acting analogues of luteinizing hormone-releasing hormone (LHRH). Encouraged by our initial success in a pilot study of one patient, we have now treated five girls with the McCune-Albright syndrome with the aromatase inhibitor testolactone, which blocks the synthesis of estrogens. Testolactone decreased the levels of circulating estradiol (P less than 0.05) and the ovarian volume (P less than 0.05), and there was a return to pretreatment levels after testolactone was stopped. During treatment, the peak responses of luteinizing hormone and follicle-stimulating hormone to stimulation by LHRH rose above suppressed pretreatment levels--significantly above pretreatment levels for follicle-stimulating hormone (P less than 0.02)--and then returned to pretreatment levels after testolactone was discontinued. Growth rates fell in three patients during treatment but could not be assessed in the other two because of bone deformities. The mean rate of bone maturation decreased and menses stopped in three of the four girls who were menstruating regularly. We conclude that testolactone is an effective treatment of precocious puberty in the McCune-Albright syndrome.

This article has been cited by other articles:

• Shulman, D. I., Francis, G. L., Palmert, M. R., Eugster, E. A., for the Lawson Wilkins Pediatric Endocrine Society, (2008). Use of Aromatase Inhibitors in Children and Adolescents With Disorders of Growth and Adolescent Development. Pediatrics 121: e975-e983 [Abstract] [Full Text]  
• Nelson, R. E., Grebe, S. K., O'Kane, D. J., Singh, R. J. (2004). Liquid Chromatography-Tandem Mass Spectrometry Assay for Simultaneous Measurement of Estradiol and Estrone in Human Plasma. Clin. Chem. 50: 373-384 [Abstract] [Full Text]  
• Teixeira, J., Fynn-Thompson, E., Payne, A. H., Donahoe, P. K. (1999). Mullerian-Inhibiting Substance Regulates Androgen Synthesis at the Transcriptional Level. Endocrinology 140: 4732-4738 [Abstract] [Full Text]  
• Cummings, E. A., Salisbury, S. R., Givner, M. L., Rittmaster, R. S. (1998). Testolactone-Associated High Androgen Levels, a Pharmacologic Effect or a Laboratory Artifact?. J. Clin. Endocrinol. Metab. 83: 784-787 [Abstract] [Full Text]  
• Lee, P. A. (1994). Advances in the Management of Precocious Puberty. CLIN PEDIATR 33: 54-61